Robert Alter, MD, John Theurer Cancer Center

mRCC: Moving to Second-Line Therapy

January 15th 2021

Factors that prompt oncologists to move to second-line therapy to treat metastatic renal cell carcinoma.

Selecting Frontline Therapy for mRCC

January 15th 2021

Variables that influence an individualized first-line treatment approach for advanced renal cell carcinoma.

Supportive Care for mRCC: Current Practices

January 8th 2021

Drs Robert Alter and Robert Motzer discuss the rationale and use of surgery as supportive care to treat appropriate patients with metastatic renal cell carcinoma.

Treatment Planning and Risk Assessment in mRCC

January 8th 2021

The importance of risk assessment when selecting frontline therapy to treat advanced renal cell carcinoma and factors to consider when talking with patients about goals of therapy.

mRCC Risk Assessment and Treatment Options

December 23rd 2020

Preferred treatment regimens that incorporate novel therapies used to treat patients with metastatic renal cell carcinoma based on risk status.

Risk Stratification in Renal Cell Carcinoma

December 23rd 2020

A historical overview regarding the development of parameters used to help stratify risk in patients with renal cell carcinoma and the relevance of current models in the context of selecting systemic therapy to treat appropriate patients.

Newly Diagnosed RCC: Treatment Planning

December 18th 2020

Guidelines and recommendations by clinicians on treatment approaches for newly diagnosed renal cell carcinoma and regimens in the pipeline that may impact future treatment.

Supportive Care and Systemic Therapy for RCC

December 18th 2020

Advice to health care providers on when to refer patients for further assessment of potential renal cell carcinoma and insight on the types of diagnostic tests used to help confirm a diagnosis in the era of molecular testing.

Emerging Therapies for Relapsed/Refractory MRCC

December 14th 2020

The Future Treatment Landscape of RCC

December 14th 2020

The Role of Combination Treatment in RCC

December 14th 2020

Impact of the Phase 3 CheckMate 9ER Trial on Practice

December 14th 2020

The Role of VEGF TKI Monotherapy

December 14th 2020

Newly Diagnosed RCC: KEYNOTE-426 and CheckMate-214

December 14th 2020

Risk Assessment and Diagnostic Work-up

December 14th 2020

Improved Outcomes With Novel and Combination Therapies

December 14th 2020

Tumor Biology in Favorable to Poor-Risk RCC

December 14th 2020

The Biology of RCC and Improved Treatment Outcomes

December 14th 2020

Renal Cell Carcinoma and Novel Therapies

December 11th 2020

As the biology of renal cell carcinoma becomes better understood, so does the management of the disease, including the use of novel therapies.